‘Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption’
Version of Record online: 13 OCT 2013
© 2013 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Volume 13, Issue 1, pages 102–110, February 2014
How to Cite
De Lorenzo, M. S., Chen, W., Baljinnyam, E., Carlini, M. J., La Perle, K., Bishop, S. P., Wagner, T. E., Rabson, A. B., Vatner, D. E., Puricelli, L. I. and Vatner, S. F. (2014), ‘Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption’. Aging Cell, 13: 102–110. doi: 10.1111/acel.12152
- Issue online: 16 JAN 2014
- Version of Record online: 13 OCT 2013
- Accepted manuscript online: 19 AUG 2013 10:23PM EST
- Manuscript Accepted: 10 AUG 2013
- National Institutes of Health. Grant Number: AG027211
- Diversity Supplement Program. Grant Number: AG027211-02S1
- The Josiah Macy, Jr. Foundation. Grant Number: 5-46787-B
- New Jersey Medical School Hispanic Center of Excellence
- Health Resources and Services Administration. Grant Number: D34HP16048
Fig. S1 Genetically modified AC5KO crossed with MMTV-Her-2-Neu mice.
Fig. S2 AC5 inhibitor reduces cell proliferation, adhesion and migration.
Fig. S3 AC5 inhibitor increases apoptosis in LP07 cells.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.